Via: OncoMed
REDWOOD CITY, Calif., April 19, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), presented new data related to its GITRL-Fc immuno-oncology therapeutic candidate at the American Association of Cancer Research (AACR) Meeting. OncoMed plans to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its GITRL-Fc candidate in late 2016/early 2017.
In two poster presentations, OncoMed researchers highlighted the differentiating characteristics and preclinical efficacy of this therapeutic candidate. OncoMed's GITRL-Fc is engineered using a novel single-gene linkerless GITR ligand trimer that binds to glucocorticoid-induced tumor necrosis factor receptor. GITRL-Fc appears to act by increasing effector T-cell activation and proliferation and reducing regulatory T-cell mediated immune suppression, resulting in a potent Th1 immune response. Single-agent GITRL-Fc demonstrated profound anti-tumor activity in multiple syngeneic mouse tumor models and achieved statistically significantly greater anti-tumor activity compared with GITR agonist antibody. Notably, GITRL-Fc did not induce the broad release of cytokines in the plasma and spleen observed with the GITR agonist antibody, suggesting the potential for an improved safety profile relative to agonist antibodies.
"We believe our approach to GITR activation, using the human ligand trimer that binds to the GITR receptor, will result in more effective activation and a more specific and potent immune response compared to other approaches. In a series of preclinical studies presented at the AACR Annual Meeting, OncoMed's GITRL-Fc demonstrated superior anti-tumor activity to an agonist antibody and induced complete tumor regressions as a single agent. Further, the broad cytokine release observed with GITR agonist antibodies was not observed using the GITR ligand approach," said Austin Gurney, PhD, co-Chief Scientific Officer and Senior Vice President, Molecular and Cellular Biology.
Read More: http://investor.shareholder.com/oncomed/releasedetail.cfm?ReleaseID=965731
RSS Feed
